Advanced Medical Solutions is not a household name, but its products close wounds and stop bleeding in operating theatres worldwide. The Cheshire-based MedTech has spent the past two years reshaping itself around a much larger surgical business, anchored by the 2024 Acquisition of France's Peters Surgical. That deal helped lift 2025 Revenue by nearly a third. Yet a July 2026 trading update showed first-half growth slowing sharply, as order timing and a deliberate European de-stocking took the edge off momentum. The supplied headline asks whether tissue-healing growth and the Peters deal can 'power the next leg higher'. With the shares near 281p and the group worth around £620m, this article weighs the acquisition-fuelled expansion against a distinctly more mixed near-term picture.
What the Company Does
Advanced Medical Solutions (LSE:AMS) is a UK-headquartered medical-technology group specialising in tissue-healing products — the adhesives, sutures, sealants, haemostats and dressings used to close and manage wounds. It runs two divisions. The larger, Surgical, sells tissue adhesives under the LiquiBand and Liquifix brands, surgical sutures and haemostats through RESORBA and Peters Surgical, and collagen-based biosurgical devices via Syntacoll. The smaller Advanced Woundcare division makes silver alginate and foam dressings, including the ActivHeal range, often supplied to other companies under their own labels.
Geographically the group is broad, selling across Europe, North America and beyond, with a growing push to sell directly in European markets rather than through distributors. Its customers are hospitals, surgeons and healthcare distributors, and Demand is underpinned by the steady, relatively non-cyclical need for surgery and wound management. In competitive terms AMS is a specialist operating alongside far larger med-tech multinationals, competing on product performance, breadth and price.
Why the Stock Is in Focus
AMS is in focus for two connected reasons: a transformational acquisition and a suddenly softer growth rate. In 2024 it bought Peters Surgical, a European specialist in surgical sutures, mechanical haemostasis and internal cyanoacrylate devices, for an Enterprise value of €141.4m. Peters generated around €84m of revenue in the year to December 2023 and has since added roughly £74m of annualised revenue to the group, turning Surgical into much the larger of AMS's two divisions and driving reported 2025 revenue up 29%.
The question now is momentum. In a trading update on 20 July 2026, AMS reported first-half revenue of £115.2m, up from £110.8m — growth of just under 4%, with some orders slipping into early July and European de-stocking as the group shifts towards direct sales. Management nonetheless kept its full-year EBITDA guidance, framing the softness as timing rather than trend.
Latest Financial Picture
The 2025 full-year results, reported in March 2026, were strong. Revenue rose 29% to £228.9m, from £177.5m, with Surgical up 35% (reported) to £183.5m and Advanced Woundcare up 9% to £45.4m. Adjusted EBITDA climbed 24% to £49.9m, adjusted pre-tax profit rose 15% to £33.9m, and reported pre-tax profit jumped 81% to £17.8m. Operating Cash Flow increased 67% to £32.6m, net Debt improved to £50.5m from £55.8m, and the total Dividend was raised 10% to 2.86p per share.
For 2026, management guided to revenue of about £245.3m and adjusted EBITDA of roughly £55.2m. The July trading update, with first-half revenue of £115.2m, keeps the group tracking towards that full-year EBITDA target, but implies a heavier second-half weighting after the order-timing and de-stocking effects of the first half. On a Market Capitalisation of about £620m at 281p on 12 August 2026, the shares are valued well above the group's reported profit base.
The Bull Case
The bull case is that AMS is a higher-quality, faster-growing Business than before Peters. The deal has broadened the product range, deepened its surgical Franchise and, crucially, created scope to sell directly in Europe rather than sharing Margin with distributors — the very shift causing short-term de-stocking now, but promising better Economics later. Strong 2025 cash generation, falling net debt and a rising dividend point to a financially disciplined operation.
Underlying demand is attractive: surgery and wound care are structurally growing, relatively recession-resistant end-markets. If management delivers the guided £55.2m of 2026 adjusted EBITDA and realises the promised Peters cost and cross-selling synergies, the current softness could prove a pause rather than a peak — supporting the 'next leg higher' thesis.
The Bear Case
The bear case starts with that slowdown. First-half 2026 revenue growth of under 4% is a long way from 2025's 29%, and while management blames timing and a deliberate European de-stocking, it leaves the full-year target reliant on a stronger second half. Much of 2025's headline growth came from acquiring Peters rather than from organic expansion, and lapping that boost makes future comparisons harder.
There are structural risks too. AMS reports in sterling but sells globally, so currency swings can distort results. Integration of Peters and Syntacoll still carries execution risk, and net debt of £50.5m, though falling, reflects the cost of the deal. At roughly £620m of Market Value against reported pre-tax profit of £17.8m, the rating leaves little room for disappointment, and a growth engine that leans on acquisitions must keep finding deals to sustain the pace.
What Could Move the Stock Next?
The most important near-term catalyst is AMS's full interim results for the six months to 30 June 2026, expected in the autumn following July's trading update, which will show whether margins and cash generation held up despite the softer top line. Delivery against the full-year guidance of about £245.3m of revenue and £55.2m of adjusted EBITDA will be scrutinised, as will evidence that the European de-stocking is temporary and that the shift to direct selling is lifting margins. Progress on Peters and Syntacoll synergies, currency movements, and any further bolt-on acquisitions could also move the shares.
Outlook
Can tissue-healing growth and the Peters deal power the next leg higher? The evidence to 12 August 2026 is genuinely two-sided. Peters has transformed AMS's scale and lifted 2025 revenue by 29%, and the group throws off cash, pays a rising dividend and operates in resilient end-markets — all supportive of the bullish reading. But the first half of 2026 was a clear cooling, with growth under 4% and a full-year target now skewed to the second half. On our reading, AMS remains a solid, cash-generative medtech whose acquisition-led step-change is real, but whose next leg higher depends on turning the Peters deal into durable organic growth and margin gains. The autumn interim results should reveal whether the soft patch is timing or something more lasting.






Please wait processing your request...